Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glioblastoma Multiforme

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    115 result(s) found for: Glioblastoma Multiforme. Displaying page 2 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2009-012186-63 Sponsor Protocol Number: LWNO 0901 Start Date*: 2009-11-05
    Sponsor Name:Erasmus MC, more specifically for and on behalf of the department of Neurology/Neuro-Oncology
    Full Title: Landelijke Werkgroep voor Neuro-Oncologie trial (LWNO 0901) Randomized phase II study of Bevacizumab versus Bevacizumab plus Lomustine in patients with recurrent Glioblastoma: the BELOB trial
    Medical condition: Patients with recurrent glioblastoma multiforme who failed combined chemo-irradiation with temozolomide.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10018336 Glioblastoma LLT
    12.0 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000608-24 Sponsor Protocol Number: 15102014 Start Date*: 2015-04-09
    Sponsor Name:Aarhus University Hospital
    Full Title: TMS Electrochemotherapy for Glioblastoma Multiforme
    Medical condition: Glioblastoma Multiforme (WHO grade IV brain tumor)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000921-61 Sponsor Protocol Number: NONK-3/NOA-12 Start Date*: 2012-04-25
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty
    Full Title: A phase I/II, randomized, open-label, multi-centre study of BIBF1120 + reirradiation (R-RT) versus reirradiation in the treatment of patients with first or second progression of glioblastoma
    Medical condition: glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001078-34 Sponsor Protocol Number: 07-09-04/07 Start Date*: 2008-09-29
    Sponsor Name:Maastro Clinic
    Full Title: Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomide
    Medical condition: Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomide
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018336 Glioblastoma LLT
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002751-10 Sponsor Protocol Number: ELDCOG Start Date*: 2015-10-05
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: DIFFERENCE BETWEEN NEUROCOGNITIVE IMPACT WITH CHEMOTHERAPY AND RADIATION THERAPY HYPOFRACTIONATED TEMOZOLOMIDE AS SINGLE AGENT IN ELDERLY PATIENTS (= 70 YEARS) WITH NEWLY DIAGNOSED GLIOBLASTOMA: A ...
    Medical condition: NEWLY DIANGOSED GLIOBLASTOMA ELDERLY PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002198-40 Sponsor Protocol Number: DEN-STEM Start Date*: 2018-01-26
    Sponsor Name:Oslo University Hospital
    Full Title: Open label randomized phase II/III trial of dendritic cell immunotherapy against cancer stem cells in glioblastoma patients receiving standard therapy (DEN-STEM)
    Medical condition: Glioblastoma brain tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000383-24 Sponsor Protocol Number: D8480C00055 Start Date*: 2008-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib...
    Medical condition: Glioblastoma - a primary brain tumour
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) CZ (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002142-37 Sponsor Protocol Number: SURGE 01-07 Start Date*: 2007-08-03
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: SUNITINIB (SUTENT, SU11248) in Patients with Recurrent or Progressive Glioblastoma multiforme An Academic Prospective Single-arm Phase II Clinical Trial including Translational Research Studies
    Medical condition: Glioblastoma multiforme - WHO grade IV First progression/recurrence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000192-37 Sponsor Protocol Number: 2019_0007 Start Date*: 2021-10-04
    Sponsor Name:Hôpital Foch
    Full Title: Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide
    Medical condition: Patients with a diagnosis of Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006871-60 Sponsor Protocol Number: DIRECTOR Start Date*: 2009-06-23
    Sponsor Name:University Hospital Heidelberg, Ruprechts-Karl-University Heidelberg
    Full Title: Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma
    Medical condition: progressive or recurrent glioblastoma after first surgery for glioblastoma and after completion of radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001977-13 Sponsor Protocol Number: 020221 Start Date*: 2012-08-01
    Sponsor Name:Northwest Biotherapeutics Inc
    Full Title: A Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells (DC) pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM)
    Medical condition: Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004457-15 Sponsor Protocol Number: EMD 121974-012 Start Date*: 2010-08-13
    Sponsor Name:Merck KGaA
    Full Title: Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter, open-label Phase II study, investigating two cilengitide regimens in combin...
    Medical condition: Newly diagnosed glioblastoma multiforme with unmethylated MGMT gene promoter status
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Prematurely Ended) FR (Completed) HU (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-013421-42 Sponsor Protocol Number: APG101_CD_002 Start Date*: 2009-12-01
    Sponsor Name:Apogenix GmbH
    Full Title: A phase II, randomized, open-label, multi-centre study of weekly APG101 + reirradiation versus reirradiation in the treatment of patients with first or second progression of glioblastoma
    Medical condition: Glioblastoma Multiforme (first or second progression)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-003896-35 Sponsor Protocol Number: EORTC 26041_22041 Start Date*: 2005-08-01
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBM
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    7.1 10018337 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) AT (Completed) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-006143-26 Sponsor Protocol Number: 2019/ABM/01/00062 Start Date*: 2021-05-02
    Sponsor Name:Śląski Uniwersytet Medyczny w Katowicach
    Full Title: A Single center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of neoadjuvant and adjuvant Pembrolizumab on top of standard Chemo-Radiotherapy (Stupp protocol) in Treatment of Pa...
    Medical condition: Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003774-32 Sponsor Protocol Number: N/A Start Date*: 2022-01-26
    Sponsor Name:DIPARTIMENTO BIOMEDICINA E PREVENZIONE UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
    Full Title: Enhancing Treatment in Persistent Glioblastoma through AGuIX Nanoparticles for Precision Radiotherapy (NanoGBM-Precision): A Phase II, monocenter, open-label, single-arm, no-profit clinical trial.
    Medical condition: Persistent Glioblastoma Multiforme, grade IV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000442-39 Sponsor Protocol Number: Neo-Nivo Start Date*: 2015-08-17
    Sponsor Name:Clinica Universidad de Navarra/Universidad de Navarra
    Full Title: PHASE II STUDY OF NEOADJUVANT NIVOLUMAB IN PATIENTS WITH GLIOBLASTOMA MULTIFORME
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000200-23 Sponsor Protocol Number: 2017-BN-001 Start Date*: 2017-05-04
    Sponsor Name:UZ Brussel
    Full Title: Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma
    Medical condition: recurrent glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001949-26 Sponsor Protocol Number: 26062-22061 Start Date*: 2009-05-05
    Sponsor Name:EORTC European Organisation for Research and Treatment of Cancer
    Full Title: A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS
    Medical condition: Elderly (>65 years of age) patients with newly diagnosed, and histopathologically confirmed, glioblastoma multiforme (GBM, WHO grade IV) , who have had prior surgery/biopsy at diagnosis and who are...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004058-17 Sponsor Protocol Number: CV-006 Start Date*: 2016-02-22
    Sponsor Name:CytoVac A/S
    Full Title: An open-label, randomised, Phase II study to investigate the efficacy and safety of ALECSAT treatment as an add-on therapy to radiotherapy and temozolomide in patients with newly diagnosed gliobl...
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 04:34:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA